Neuroinflammation is increasingly recognized as a driving force in neurological disease. When the brain encounters injury, infection, or toxic stimuli, resident glial cells react by releasing signalling molecules called pro-inflammatory cytokines, along with reactive oxygen and nitrogen species that can damage proteins, lipids, and DNA. In the short term, this response is protective, helping to contain threats and coordinate repair. But when the inflammatory state becomes chronic, it contributes to the progression of conditions including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Astrocytes sit at the centre of this process: they can either amplify inflammation or help resolve it, depending on the context and duration of the insult. Finding molecules that tip astrocytes toward a calmer, more balanced state is therefore a major goal of neuroinflammation research.

Ellagic acid has attracted attention precisely because of its dual antioxidant and anti-inflammatory credentials. Chemically, the molecule pairs a hydrophilic face bearing four hydroxyl groups and two lactone groups with a lipophilic backbone of two biphenyl rings, a structure that allows it to neutralize a broad spectrum of reactive species, including hydroxyl radicals and peroxynitrite, and to chelate metal ions that would otherwise catalyze free-radical production. Previous work has shown the compound protecting astrocytes from cadmium-induced oxidative injury, reducing nitrite production in macrophages exposed to inflammatory triggers, and easing mitochondrial dysfunction in heart cells exposed to the antipsychotic drug clozapine. What remained less clear was how ellagic acid would perform in astrocytes specifically provoked by a bacterial inflammatory stimulus.

To find out, the team prepared primary astrocyte cultures from the cerebral cortices of newborn Wistar rats, growing the cells for twenty days until they matured, following an ethically approved protocol at the Federal University of Pelotas. The cultures were then pretreated with ellagic acid at three concentrations, 50, 100, and 200 micromolar, for 48 hours before being exposed to lipopolysaccharide, or LPS, a component of the outer membrane of Gram-negative bacteria and a standard laboratory tool for switching on inflammatory pathways. LPS works by engaging Toll-like receptor 4 on the astrocyte membrane, which triggers an intracellular cascade that ramps up the expression of inflammatory mediators such as interleukin 1-beta, interleukin 6, and tumour necrosis factor-alpha, while mitochondrial dysfunction floods the cell with additional reactive species.

The inflammatory insult did exactly what the researchers expected. LPS exposure significantly reduced astrocyte viability as measured by the MTT assay, which tracks mitochondrial metabolic activity, while paradoxically increasing cell proliferation as measured by the sulforhodamine B protein-staining assay, a combination the authors interpret as distinct metabolic and growth responses to the same stimulus. LPS also drove up levels of reactive oxygen species and nitrite, drained the cells’ pool of protective sulfhydryl groups, and suppressed the activities of three key antioxidant enzymes: superoxide dismutase, catalase, and glutathione S-transferase. In other words, the cells were simultaneously producing more damaging oxidants and losing the enzymatic defences that would normally clear them, a textbook picture of oxidative stress.

Ellagic acid treatment substantially reversed this damage. At 100 and 200 micromolar, the compound significantly attenuated the LPS-induced rise in reactive oxygen species and nitrite levels, restored sulfhydryl content, and boosted the activities of superoxide dismutase and catalase back toward healthy levels; glutathione S-transferase activity was rescued even at the lowest dose tested. The compound also preserved cell viability at all three concentrations and curbed the abnormal proliferation at the highest dose. The authors suggest that the effect likely reflects both direct radical scavenging by the polyphenol’s chemical structure and a strengthening of the cells’ endogenous antioxidant machinery, possibly through the Nrf2 signalling pathway, a master regulator of antioxidant enzyme expression that ellagic acid has been shown to activate in other systems.

The anti-inflammatory results were more nuanced, and arguably more interesting. On the gene-expression front, LPS drove up messenger RNA levels for tumour necrosis factor-alpha, interleukin 1-beta, interleukin 6, and glycogen synthase kinase-3 beta, a multifunctional kinase with known roles in inflammatory regulation. Ellagic acid pretreatment at 100 micromolar prevented the increases in tumour necrosis factor-alpha and interleukin 1-beta, consistent with prior evidence that the compound can dampen the NF-kappa-B pathway, the transcriptional hub through which LPS switches on inflammatory genes. At the protein level, the picture diverged: LPS raised extracellular interleukin 6, but ellagic acid did not significantly change it, even though the compound had raised interleukin 6 mRNA. The authors caution that transcription and secretion follow different timelines and regulatory steps, so a single time point cannot capture the full story. Notably, LPS also suppressed interleukin 10, an anti-inflammatory cytokine, and ellagic acid at 100 micromolar fully prevented that reduction, a result that points toward selective rebalancing rather than blanket immune suppression.

The glycogen synthase kinase-3 beta finding demands particular care in interpretation. Ellagic acid increased the mRNA for this kinase in LPS-exposed astrocytes, and earlier work by Beurel and Jope showed that glycogen synthase kinase-3 beta activity can positively regulate interleukin 6 production in glial cells, which might suggest a pro-inflammatory consequence. But the Brazilian team is explicit that this kinase is controlled mainly by post-translational modification, especially its phosphorylation state, not by how much of it is transcribed. Elevated mRNA does not necessarily mean elevated enzymatic activity, and the study did not measure protein levels or phosphorylation. The same honesty applies to the signalling pathways themselves: neither NF-kappa-B activation nor Nrf2 expression was directly assessed in these experiments, so both remain plausible but unproven mechanisms for the effects observed.

The authors also lay out the study’s structural limitations with unusual thoroughness. The cultures were prepared by a standardized protocol but were not purified or checked immunocytochemically, so other glial cell types may have been present and contributing to the measurements. There were no ellagic-acid-only groups, which makes it harder to separate the compound’s intrinsic effects from its modulation of the LPS response, particularly for the interleukin 6 and glycogen synthase kinase-3 beta mRNA results. All analyses were performed at a single early time point, three hours after LPS exposure, and the key cytokines were examined only at the transcriptional level. And perhaps most importantly for anyone hoping to translate the findings, the concentrations used in the dish may not correspond to levels achievable in the human body, because ellagic acid has limited bioavailability and complex pharmacokinetics.

Those caveats notwithstanding, the overall picture is coherent and encouraging for a specific, testable idea: that a common dietary polyphenol can help inflamed astrocytes hold the line. In the study’s summary model, ellagic acid preserved cell viability, rebuilt antioxidant defences, trimmed the expression of two major pro-inflammatory cytokines, restored the anti-inflammatory cytokine interleukin 10, and pushed the astrocytic response toward what the authors describe as a more balanced and controlled state rather than a generalized shutdown of inflammatory signalling. The team frames the work as a foundation rather than a finish line, calling for time-course experiments, protein and phosphorylation measurements, direct assessment of the NF-kappa-B, Nrf2, MAPK, and glycogen synthase kinase-3 beta pathways, and eventually more complex models of neuroinflammation that capture the cellular richness of a living brain. For now, the humble pomegranate has once again supplied a molecule worth watching.

Subject of Research: Effects of the dietary polyphenol ellagic acid on oxidative stress and inflammatory responses in lipopolysaccharide-stimulated primary astrocyte cultures

Article Title: Ellagic acid regulates astrocytic responses under inflammatory conditions in primary astrocyte cultures: effects on oxidative stress, inflammatory cytokines, and glycogen synthase kinase-3β

Article References: da Rosa, T. M., da Silveira, L. M., Bona, N. P., Saraiva, J. T., da Silva, J. A., Domingues, W. B., de Souza, L. P., Nascimento, M. C., Campos, V. F., Stefanello, F. M., de Andrade, C. M., Pedra, N. S., & Spanevello, R. M. (2026). Ellagic acid regulates astrocytic responses under inflammatory conditions in primary astrocyte cultures: effects on oxidative stress, inflammatory cytokines, and glycogen synthase kinase-3β. Molecular Biology Reports, 53(1), Article 1534. https://doi.org/10.1007/s11033-026-12671-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12671-4

Keywords: ellagic acid, astrocytes, neuroinflammation, lipopolysaccharide, oxidative stress, inflammatory cytokines, GSK3-beta, antioxidant enzymes, NF-kappa-B, Nrf2 pathway, primary cell culture, Molecular Biology Reports

The story begins with the pulp–dentin complex itself, the integrated functional unit that keeps a living tooth alive. Odontoblasts line the periphery of the pulp space and extend processes into the dentinal tubules, serving as sentinels that detect external threats and deposit tertiary dentin as a defensive barrier. Fibroblasts, the most abundant stromal cells in the pulp, produce and maintain the extracellular matrix, while dental pulp stromal cells, or DPSCs, carry remarkable regenerative and immunomodulatory properties, including the ability to differentiate into odontoblast-like cells and contribute to reparative dentin formation. When caries breaches the enamel and advances through dentin, a dynamic network of interdependent relationships emerges among odontoblasts, stromal cells and immune cells, and it is within this network that the Korean team went hunting for the rules of communication.

Macrophages were the obvious suspects. These innate immune cells are the pulp’s frontline defenders, recognizing pathogen-associated molecular patterns through Toll-like receptors and mounting inflammatory responses against bacterial invasion. But macrophages are also indispensable mediators of tissue remodeling, secreting trophic factors such as TGF-beta, VEGF and IGF-1 that regulate the proliferation, migration and differentiation of resident progenitor cells. To see how macrophages behave during actual disease, the researchers examined human dental pulp tissue from healthy teeth and teeth with moderate or severe caries, using immunofluorescence to track CD68-positive macrophages. In healthy pulp, macrophages were sparsely distributed throughout the tissue. As caries progressed, their numbers surged, and they clustered beneath regions of advanced decay near the odontoblast layer.

The most striking observation was physical contact. The proportion of macrophages in intimate contact with Thy-1-positive DPSCs rose from 11.2 percent in healthy teeth to 23.7 percent in moderate caries and 48.7 percent in severe caries, suggesting that these immune–stromal encounters are not incidental but part of an organized defensive response. In vitro, the team co-cultured differentiated human macrophages with primary DPSCs and watched the two cell types lock together, extending lamellipodia and filopodia-like protrusions visible under scanning electron microscopy. Macrophages in direct contact with DPSCs showed markedly increased filamentous actin intensity, particularly at the cell–cell interface, a hallmark of intercellular adhesion mechanisms at work.

What molecule was doing the gluing? The researchers profiled adhesion components by RNA sequencing and tested two hypotheses: direct homophilic binding between matching cell-adhesion molecules, or indirect communication through an extracellular matrix intermediary. The homophilic route failed, as macrophages and DPSCs showed no matching cadherin or ICAM-family expression patterns. The matrix route, however, lit up. DPSCs predominantly expressed fibronectin and type I collagen, while macrophages abundantly expressed the integrin subunits ITGA5 and ITGB1, the canonical receptors for fibronectin. Computational ligand–receptor prediction with CellPhoneDB confirmed statistically significant interactions between fibronectin on DPSCs and multiple integrin receptors on macrophages. Structured illumination microscopy then revealed that integrin alpha-5 clusters on macrophages aligned precisely with fibronectin deposited on the DPSC surface, forming the activated, clustered configuration characteristic of functional adhesion.

The functional proof was decisive. A synthetic RGD peptide that blocks integrin–ligand binding reduced macrophage–DPSC contact in a concentration-dependent manner, while collagenase treatment had no effect. CRISPR-Cas9 knockout of ITGA5 in macrophages slashed both the proportion and the duration of contacts with DPSCs, as live imaging over 48 hours demonstrated. Downstream, phosphorylated focal adhesion kinase rose in macrophages cultured on fibronectin-coated surfaces and climbed even higher in co-culture, implicating the fibronectin–integrin–FAK axis as the signaling conduit between the two cell types.

Then came the transformation. Bulk RNA sequencing of sorted macrophages revealed that co-culture with DPSCs shifted their chemokine repertoire dramatically: pro-inflammatory CCL2 and CCL3 were downregulated, while a suite of ELR-positive CXC chemokines—CXCL2, CXCL3, CXCL5, CXCL6 and CXCL8—known for their angiogenic activity were upregulated, alongside VEGFA. Macrophages seeded on fibronectin-coated plates upregulated these pro-angiogenic factors in a dose-dependent fashion, and silencing FN1 in DPSCs suppressed the effect, confirming fibronectin as the trigger. Flow cytometry showed the macrophages shifting toward an M2-like phenotype, with CD206 rising while CD86 stayed flat. The mechanism ran through NF-kappa-B: p65 accumulated in both cytoplasm and nucleus of co-cultured macrophages, and a live-cell GFP reporter showed that fibronectin-coated surfaces drove NF-kappa-B activity roughly 90 percent higher than LPS treatment, while collagen 1 surfaces did nothing.

The consequences for blood vessels were immediate. Conditioned medium from macrophage–DPSC co-cultures dramatically enhanced tube formation by human umbilical vein endothelial cells, increasing the number of junctions, segments and meshes compared with medium from either cell type alone. Endothelial cells exposed to co-culture medium also showed fewer apoptotic membrane blebs and reduced cleaved caspase-3, indicating improved survival. Blocking CXCR2 or VEGFR signaling with specific inhibitors attenuated both angiogenesis and endothelial survival, pinning the effect on the newly identified chemokine and VEGF pathways. An integrated single-cell RNA sequencing atlas of nearly 20,000 human pulp cells, analyzed with the CellChat framework, independently confirmed the story in real tissue: as caries progressed from healthy to severe, total cell–cell interactions exploded from 278 to 2,470, macrophage–endothelial CXCL signaling strengthened markedly, and macrophages emerged as central hubs of the angiogenic communication network.

The final test was translational. In a canine model of pulp revascularization using immature premolar teeth, the researchers applied fibronectin as a final canal irrigation and on a collagen sponge scaffold, following American Association of Endodontists guidelines in a split-mouth design with 22 roots per group. Eight weeks later, micro-computed tomography showed that fibronectin-treated roots had significantly greater cross-sectional dentin area (3.40 versus 2.39 square millimeters) and far more frequent apical closure (59.1 percent versus 22.7 percent). Histology revealed organized layers of polarized odontoblast-like cells, dentinal tubule-like structures and dentin sialoprotein-positive staining in the treated roots, along with abundant new blood vessels and CD14-positive, CD163-positive M2 macrophages in the stromal region—precisely the cellular signature the in vitro work had predicted. Fibronectin itself was localized along the regenerated odontoblast layer, mirroring its arrangement in healthy human pulp.

The implications reach well beyond the dental chair. Because fibronectin is an endogenous protein with established biocompatibility, it carries minimal risk of adverse reactions compared with exogenous growth factors or synthetic biomaterials, and its angiogenic capabilities suggest potential applications in soft-tissue regeneration, bone-tissue engineering and scaffold-based therapies across regenerative medicine. For the millions of children and adults with immature necrotic teeth—a population for whom conventional root canals arrest root development and increase fracture risk—the prospect of a simple, biologically grounded irrigation solution that coaxes the body’s own immune and stromal cells into rebuilding a living pulp is genuinely tantalizing. The authors caution that species differences in pulp biology, optimization of delivery parameters and long-term follow-up studies all stand between this canine model and human clinical practice. But the core discovery stands: a humble matrix protein, long viewed as passive scaffolding, is in fact an active conductor of the immune–stromal orchestra that turns a damaged, infected pulp environment into a regenerative niche. Teeth, it turns out, may know how to heal themselves—we just needed to learn the language they use to ask for help.

Subject of Research: Fibronectin-mediated macrophage–stromal cell crosstalk driving angiogenesis and regeneration of the dental pulp–dentin complex

Article Title: Fibronectin-guided immune–stromal cell crosstalk promotes angiogenesis in pulp–dentin complex regeneration

Article References: Jeong, S., Park, S. Y., Ku, H., Eom, B. S., Kim, D., & Kim, J. M. (2026). Fibronectin-guided immune–stromal cell crosstalk promotes angiogenesis in pulp–dentin complex regeneration. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01863-4

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01863-4

Keywords: fibronectin, macrophages, dental pulp stem cells, angiogenesis, dental caries, pulp revascularization, extracellular matrix, integrins, regenerative dentistry, NF-kappa-B, chemokines, tissue regeneration

The research, led by Murat Çakır of Yozgat Bozok University together with colleagues at Yozgat Bozok University, Osmaniye Korkut Ata University, and Inonu University, focused on fatty acid amide hydrolase, or FAAH, the enzyme responsible for breaking down anandamide, one of the body’s principal endogenous cannabinoids. Anandamide and its molecular cousins are not merely the chemicals that give cannabis its effects; they are native signaling molecules that the body deploys to fine-tune pain, immune responses, inflammation, and cell survival. By inhibiting FAAH, URB597 prevents anandamide from being rapidly degraded, effectively amplifying the body’s own anti-inflammatory signaling without introducing any plant-derived or psychoactive compounds. This strategy of augmenting endocannabinoid tone has attracted growing interest as researchers probe its potential in inflammatory and ischemic diseases.

To test whether this approach could protect the kidneys during sepsis, the investigators used the cecal ligation and puncture model, widely regarded as the gold standard for reproducing polymicrobial sepsis in rodents. In this model, the cecum is ligated and punctured, allowing intestinal bacteria to spill into the peritoneal cavity and trigger a systemic infection that closely mirrors the clinical course of septic shock in patients. Forty male Sprague-Dawley rats were divided into four groups of ten animals each: a healthy control group, a sepsis group receiving no treatment, and two sepsis groups treated with URB597 at doses of either 0.3 or 0.6 milligrams per kilogram of body weight. Critically, the drug was administered intraperitoneally within five minutes of the sepsis induction, a timing designed to test whether early intervention could blunt the inflammatory cascade before it inflicted irreversible damage.

Twenty-four hours after sepsis was induced, the researchers collected blood and kidney tissue for a battery of biochemical, histopathological, and immunohistochemical analyses. The results in the untreated septic animals were stark. Serum levels of blood urea nitrogen and creatinine, the classic clinical markers of kidney dysfunction, rose significantly, as did neutrophil gelatinase-associated lipocalin, or NGAL, an earlier and more sensitive biomarker of tubular injury that has gained traction in nephrology for flagging kidney damage before conventional blood tests change. Alongside these functional markers, the septic rats showed elevated circulating levels of the pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin-1 beta, signaling molecules that drive much of the tissue destruction seen in sepsis.

Under the microscope, the kidneys of untreated septic rats displayed the characteristic hallmarks of acute injury: disrupted tubular architecture, cellular swelling, and inflammatory infiltration. But in the animals that received URB597, the picture changed dramatically. Both doses of the drug significantly reduced the sepsis-induced elevations in BUN, creatinine, NGAL, TNF-alpha, and IL-1 beta compared with untreated septic controls, and the histopathological damage to the kidney tissue was visibly attenuated. Interestingly, when the two doses were compared head to head, the researchers found no significant differences between them in the serum biochemical parameters, suggesting that even the lower dose captured most of the protective effect within the timeframe studied.

The mechanistic heart of the study lies in its immunohistochemical findings, which traced the protective effect to a specific molecular pathway. Toll-like receptor 4, or TLR4, is a pattern-recognition receptor on immune and kidney cells that acts as an alarm bell for bacterial components, launching a signaling chain that activates nuclear factor-kappa B, or NF-kappa B, a transcription factor often described as the master switch of inflammation. When NF-kappa B is activated, its inhibitory protein I-kappa B-alpha is phosphorylated and degraded, allowing the transcription factor to enter the nucleus and switch on genes encoding TNF-alpha, interleukin-1 beta, and interleukin-6. In the septic rats, the researchers detected strong renal immunoreactivity for TLR4, phosphorylated NF-kappa B, and phosphorylated I-kappa B-alpha, confirming that this inflammatory axis had been ignited in the kidney tissue itself.

URB597 treatment significantly dampened all of these molecular markers. The treated animals showed reduced renal immunoreactivity for TLR4, phosphorylated NF-kappa B, phosphorylated I-kappa B-alpha, TNF-alpha, IL-1 beta, and IL-6, indicating that the drug had effectively turned down the volume on the kidney’s local inflammatory response rather than merely masking systemic markers. This pathway-level suppression is significant because the TLR4/NF-kappa B axis has been implicated not only in septic kidney injury but also in renal damage from ischemia-reperfusion and toxic insults, meaning that a drug acting here could theoretically have broad nephroprotective applications.

Equally important was the drug’s effect on apoptosis, the programmed cell death process that contributes to the loss of functional tubular cells in septic kidneys. The researchers measured renal levels of cleaved caspase-3, the executioner enzyme that disassembles the cell from within, and caspase-8, an initiator caspase that relays death signals from inflammatory pathways. Both were elevated in the septic animals and significantly reduced by URB597 treatment. This dual action, suppressing both the inflammatory cascade and the apoptotic machinery downstream of it, suggests that boosting endocannabinoid signaling protects kidney tissue at multiple points along the injury pathway rather than targeting a single vulnerable node.

The findings dovetail with a growing body of literature on the endocannabinoid system in kidney disease. Previous work has shown that FAAH inhibition or genetic deletion protects against renal fibrogenesis after ischemia-reperfusion injury and ameliorates cisplatin-induced nephropathy in mice, while other studies have demonstrated that endocannabinoid degradation inhibitors reduce leukocyte adhesion and improve microvascular perfusion in experimental endotoxemia. Elevated levels of the endocannabinoids anandamide and 2-arachidonoylglycerol have even been proposed as prognostic markers in septic patients, hinting that the body may naturally ramp up this protective system in response to infection. The present study extends this line of inquiry directly into sepsis-associated acute kidney injury, one of the most clinically consequential settings in which the endocannabinoid system had remained comparatively underexplored.

As with all preclinical work, considerable distance separates a rat model from the intensive care unit. The cecal ligation and puncture model, while rigorous, cannot fully capture the heterogeneity of human sepsis, and the drug was given within minutes of sepsis induction, a therapeutic window that rarely exists in clinical practice where patients arrive hours or days after infection begins. Dosing, safety, and efficacy in humans remain entirely untested, and URB597 itself has had a complicated development history as a clinical candidate. Nevertheless, the study provides a clear and mechanistically grounded proof of concept: enhancing the body’s own cannabinoid signaling through FAAH inhibition can measurably reduce kidney injury, inflammation, and cell death in experimental sepsis, acting through the well-characterized TLR4/NF-kappa B pathway. For a condition in which supportive care remains the mainstay of treatment and no specific drug currently protects the kidneys from septic damage, that proof of concept is a development worth watching closely as the field moves toward translating endocannabinoid science into nephroprotective therapies.

Subject of Research: Protective effects of FAAH inhibition with URB597 in experimental sepsis-associated acute kidney injury

Article Title: URB597 attenuates experimental sepsis-associated acute kidney injury with reduced renal inflammation, apoptosis, and TLR4/NF-κB activation

Article References: Çakır, M., Aydın, A., Bircan, B., Fırat, S., & Tekin, S. (2026). URB597 attenuates experimental sepsis-associated acute kidney injury with reduced renal inflammation, apoptosis, and TLR4/NF-κB activation. Molecular Biology Reports, 53(1), Article 1631. https://doi.org/10.1007/s11033-026-12803-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12803-w

Keywords: sepsis, acute kidney injury, URB597, FAAH, endocannabinoid system, anandamide, TLR4, NF-kappa B, inflammation, apoptosis, cytokines, rat model

The motivation is industrial as much as scientific. China’s annual aquaculture yield of fresh sea cucumber exceeds 220,000 tons, generating enormous quantities of protein-rich raw material that conventional processing methods such as drying and rehydration fail to exploit at high value. The researchers, led by Zhongxing Chu of Central South University of Forestry and Technology and colleagues, reasoned that enzymatic hydrolysis could unlock that value in two directions at once: releasing short bioactive peptides with immunomodulatory potential while also reshaping the flavor profile of the resulting ingredient. What has been missing in prior work, they argue, is a systematic account of how protein structure, flavor chemistry, and peptide bioactivity are connected under a defined hydrolysis process.

To make that connection, the team subjected sea cucumber protein with a purity above 90 percent and a collagen content above 82 percent to a sequential three-enzyme digestion using pepsin, trypsin, and enterokinase, each applied at an enzyme-to-substrate ratio of 1 percent for four hours at 37 degrees Celsius. The treatment cleaved roughly 40.72 percent of the available peptide bonds, as measured by the o-phthalaldehyde colorimetric method, producing a hydrolysate dominated by short fragments. A parallel blank control without added enzymes ruled out interference from endogenous proteases in the raw material, ensuring that the observed transformations could be attributed to the deliberate enzymatic process.

The structural consequences of that digestion were documented with an unusually thorough battery of techniques. Scanning electron microscopy revealed that the native protein, an irregular and densely packed sheet-like material with smooth surfaces, was transformed into a porous, sponge-like network riddled with interconnected cavities. Fourier-transform infrared spectroscopy showed a decline in ordered alpha-helical content and a rise in random coil structures, while ultraviolet and fluorescence spectroscopy demonstrated that aromatic amino acids buried in the hydrophobic core had been exposed to the aqueous environment, with the tryptophan emission peak red-shifting from about 330 to 345 nanometers. X-ray diffraction and differential scanning calorimetry completed the picture: the hydrolysate lost the cooperative thermal denaturation behavior characteristic of intact proteins, meaning the small peptides are less prone to coagulation during food processing, a practical advantage for manufacturers.

Flavor, often treated as an afterthought in peptide research, received full analytical attention here. Using headspace solid-phase microextraction coupled with gas chromatography on an Orbitrap mass spectrometer, the team identified 147 significantly differential volatile compounds between the native protein and the hydrolysate, with 74 upregulated after digestion. Aldehydes such as hexanal and (E,E)-2,4-nonadienal, products of unsaturated fatty acid oxidation, drove the green and fatty notes, while heterocyclic compounds including 2-pentylfuran and trimethylpyrazine, likely born of Maillard reactions between newly liberated amino groups and trace reducing sugars, contributed fried and waxy aromas. The multivariate statistical models separating the two sample groups passed rigorous validation with 200 permutation tests, lending confidence to the conclusion that hydrolysis fundamentally remodeled the volatile landscape of the ingredient.

Peptide identification by liquid chromatography tandem mass spectrometry revealed roughly 9.5 amino acids as the average chain length, with most peptides falling between 0.5 and 1.5 kilodaltons, a size range favorable for intestinal absorption. Glycine and glutamine or glutamic acid dominated the amino acid composition, each exceeding 13 percent average abundance, a signature of the (Gly-X-Y) repeating motif of collagen and direct confirmation that the peptides derived from sea cucumber collagen. The peptides were overwhelmingly hydrophilic and weakly acidic, properties that improve dispersibility in aqueous food systems and reduce precipitation, and the high confidence scores of the identifications underscored the reliability of the dataset.

The screening stage is where the study’s integrative design paid off. From the mass spectrometric sequences, the researchers applied a cascade of computational tools: umami and bitterness predictors, the PeptideRanker bioactivity server, a CSM-peptides immunomodulatory model, and safety checks for toxicity, allergenicity, and water solubility. Sixteen high-confidence peptides emerged, and three candidates, FDRGF, CPPGFMG, and FFSLFCLL, cleared the thresholds of umami probability of at least 0.23, bioactivity score of at least 0.97, and non-toxic, non-bitter status. An electronic tongue then arbitrated. FDRGF, a pentapeptide with the sequence phenylalanine-aspartic acid-arginine-glycine-phenylalanine, posted an umami response of 78, second only to monosodium glutamate at 85, with minimal bitterness and astringency. CPPGFMG showed kokumi-like characteristics reminiscent of glutathione, while FFSLFCLL was undermined by noticeable bitterness. FDRGF, with the highest umami probability of 0.557 and an anti-inflammatory score of 0.78, was crowned the dual-function lead candidate.

Computational docking against three key inflammatory targets, tumor necrosis factor, AKT1, and interleukin-1 beta, predicted favorable binding for all three, with the strongest affinity for AKT1 at a binding energy of minus 9.9 kilocalories per mole. One-hundred-nanosecond molecular dynamics simulations in GROMACS confirmed that the complexes remained stable, with root mean square deviation curves converging to the 1 to 3 angstrom range and residues at the binding interface showing reduced flexibility, a sign of specific and durable engagement. These simulations, the authors note, bridge the gap between static docking snapshots and the dynamic behavior of proteins under physiological conditions, providing structural plausibility for the peptide’s presumed mechanism of interfering with inflammatory cascade initiation.

The decisive test came in RAW 264.7 macrophages, a standard mouse immune cell line. At concentrations from 6.25 to 100 micrograms per milliliter, the peptide showed no cytotoxicity, with viability remaining above 95.28 percent. When the cells were challenged with lipopolysaccharide, a bacterial toxin that drives viability down to about 84 percent and triggers classic inflammatory damage, pre-treatment with the peptide restored metabolic activity in a dose-dependent manner, peaking at 50 micrograms per milliliter. Microscopy showed cells recovering their healthy, spread-out macrophage morphology with visible pseudopodia. More tellingly, the peptide dose-dependently reduced intracellular reactive oxygen species, suppressed NF-kappa-B transcriptional activity in a dual-luciferase reporter assay, and downregulated the protein expression of interleukin-1 beta, tumor necrosis factor alpha, interleukin-6, and the inflammatory enzyme COX-2, the molecular machinery of inflammation itself.

The authors are candid about the limits of their evidence. The immunological findings rest entirely on an in vitro macrophage model of lipopolysaccharide-induced injury, which captures anti-inflammatory performance under stress but cannot represent the full sweep of innate and adaptive immune regulation, and the MTS assay measures metabolic activity rather than complete immune function recovery. Quantitative peptide yield and conversion efficiency were also not determined at this stage. Still, the study stands as a template for how modern food science can pursue two goals at once: an ingredient that delights the palate and, at least in cell culture, calms the inflammatory response. Whether the five-letter peptide FDRGF can carry that promise from the petri dish to the dinner plate will depend on animal and human studies, but as a proof of concept for flavor-functional peptides from underexploited marine protein, it is a savory result in every sense.

Subject of Research: Identification of an umami-tasting, anti-inflammatory peptide from enzymatically hydrolyzed sea cucumber protein

Article Title: Screening and identification of a novel umami peptide with in vitro anti-inflammatory potential from sea cucumber protein: Integration of flavoromics, bioinformatic prediction, molecular simulation and experimental validation

Article References: Chu, Z., Long, C., Xu, K., Zhang, X., Qin, D., Hu, Z., Zhou, Y., Luo, F., & Lin, Q. (2026). Screening and identification of a novel umami peptide with in vitro anti-inflammatory potential from sea cucumber protein: Integration of flavoromics, bioinformatic prediction, molecular simulation and experimental validation. Food Chemistry: X, 39, Article 104580. https://doi.org/10.1016/j.fochx.2026.104580

Image Credits: AI Generated

DOI: 10.1016/j.fochx.2026.104580

Keywords: sea cucumber, umami peptide, bioactive peptides, enzymatic hydrolysis, anti-inflammatory, flavoromics, molecular docking, molecular dynamics, RAW 264.7 macrophages, NF-kappa-B, collagen, food chemistry

The research team, working at the University of Florida, engineered mice in which FAPs could be selectively eliminated at will. They crossed animals carrying a tamoxifen-activated Cre recombinase driven by the Pdgfra promoter, which is active in FAPs, with mice carrying a diphtheria toxin A gene inserted into the Rosa26 locus. When adult mice, aged twelve to thirteen weeks, received five consecutive daily injections of tamoxifen, the toxin switched on inside FAPs and killed them. Three weeks later, the researchers found that FAP abundance in the muscle had plummeted by roughly 90 percent. The consequences were dramatic and systemic: total body mass and lean mass fell in both males and females, hindlimb muscles including the tibialis anterior, extensor digitorum longus and soleus shrank significantly, and even the spleen, liver and inguinal fat pads lost substantial weight, shrinking by up to 30 percent.

Crucially, the atrophy was not selective. Because the three muscles examined span a range of metabolic and contractile properties, the wasting appeared to be entirely independent of fiber type. Yet when the team tested muscle function directly, a surprising picture emerged. Absolute maximum isometric force was significantly reduced in both fast-twitch and slow-twitch muscles of the FAP-depleted mice, exactly as expected from smaller muscles. But when force was normalized to the muscle’s reduced cross-sectional area, the so-called specific force was completely unchanged. The contractile machinery inside each fiber was working perfectly fine. Even eccentric contractions, which subject muscles to damaging lengthening forces, revealed no increase in fragility. In other words, the muscle was losing quantity, not quality.

One long-standing hypothesis held that FAPs keep muscle healthy by supporting the neuromuscular junction, the synapse where nerves command fibers to contract. FAPs do cluster physically around these junctions, and previous work had suggested their deletion triggers synaptic degeneration and denervation-like atrophy. To test this rigorously, the researchers performed whole-mount immunofluorescence on the junctions of the EDL and soleus muscles, labeling presynaptic nerve terminals with antibodies against neurofilament and synaptic vesicle proteins, and postsynaptic acetylcholine receptors with fluorescently tagged alpha-bungarotoxin. The result was unambiguous: complete overlap between pre- and postsynaptic structures, intact endplate gutters, no fragmentation, and normal terminal Schwann cell morphology. Functional testing told the same story. When the team compared force produced by direct muscle stimulation against force evoked through the nerve, the ratios were equivalent in control and FAP-depleted mice, indicating flawless synaptic transmission. Molecular markers of denervation, such as shifts in acetylcholine receptor subunit genes, were also absent.

With the neuromuscular hypothesis ruled out for this acute setting, the team turned to the timeline of the wasting itself. Longitudinal body composition measurements revealed that most of the lean mass loss occurred during the active tamoxifen dosing window, not during the weeks of washout that followed. Apoptotic FAPs, identified by cleaved caspase 3 staining, were detectable as early as one day after the first injection. By day three, FAP numbers had collapsed. And by day five, the muscle was flooded with innate immune cells: myeloperoxidase-positive neutrophils and CD68-positive macrophages arrived in a massive, synchronized wave. The temporal sequence was telling. Cell death came first, immune infiltration followed, and only then did the muscle begin to visibly shrink.

Transcriptional profiling filled in the molecular plot. The researchers tracked two families of genes over time: atrogenes, which include the E3 ubiquitin ligases Trim63 and Fbxo32 and the autophagy markers Ulk1 and Sqstm1, and inflammatory chemokines and cytokines. An early spike in atrogene expression at day one occurred in both control and experimental mice and was attributed to the stress of tamoxifen treatment itself. But at day five, only the FAP-depleted muscles mounted a second, powerful surge of proteolytic gene expression. Preceding that surge, chemokine expression exploded. Ccl2, Ccl12, Cxcl1 and Cxcl2 rose fifty- to one-hundred-fold above control levels, peaking at day three, precisely before the atrogene wave. Interleukin-6, a cytokine with well-established links to muscle catabolism, climbed roughly fifteen-fold and stayed elevated. Notably, circulating IL-6 rose only modestly, showing that this was a fiercely local inflammatory response rather than a systemic one, and the entire transcriptional storm resolved by day twenty-eight, marking the atrophy as acute rather than chronic.

The most counterintuitive finding came when the researchers removed the immune cells themselves. Using clodronate liposomes to deplete macrophages and an anti-Ly6G antibody to eliminate neutrophils, they tested whether the infiltrating cells were culprits or protectors. The answer was neither simple nor expected: depleting either population, or both simultaneously, made the muscle wasting significantly worse. Even control mice with fully intact FAPs lost muscle when their myeloid cells were cleared. Macrophage depletion blunted the expression of Ccl2 and Ccl12, identifying macrophages as a likely source of those chemokines, yet this reduction failed to rescue muscle mass or fiber size. Neutrophil depletion, meanwhile, pushed Cxcl1 and Cxcl2 even higher, correlating with heightened atrogene expression and more severe atrophy. The infiltrating immune cells, it seems, perform essential housekeeping, clearing debris from the dying progenitors and resolving tissue stress, and their absence leaves the muscle more vulnerable, not less.

If the cells were not the problem, perhaps their signaling was. The team turned to pharmacology, treating mice with either SB225002, a selective antagonist of the CXCR2 receptor through which CXCL1 and CXCL2 act, or VBP15, also known as vamorolone, a dissociative anti-inflammatory steroid that inhibits the NF-kappa-B pathway, a central transcriptional regulator of wasting programs. Both interventions produced striking protection. Treated FAP-depleted mice retained their lean mass and fat mass, their muscles kept significantly more wet weight and fiber cross-sectional area, and their atrogene expression was substantially suppressed. Critically, immunofluorescence confirmed that neither drug changed the number of immune cells entering the tissue. The protection came from quieting inflammatory signaling, not from blocking infiltration. The two drugs also worked through distinguishable mechanisms: vamorolone broadly suppressed chemokine expression, while CXCR2 blockade triggered a compensatory rise in CXCL1 and CXCL2, a classic feedback loop when ligands can no longer engage their receptor.

The study’s authors are careful about what these results do and do not prove. Because eliminating FAPs necessarily involves killing them, the design cannot fully separate the loss of FAP-derived trophic support from the consequences of cell death itself. The transient drop in muscle Igf1 expression and the modest rise in myostatin hint that trophic factors may contribute, yet previous work showing that deleting Igf1 specifically from FAPs does not shrink muscle argues against trophic loss as the primary driver. The authors suggest that the early atrophy reflects the inflammatory fallout of progenitor death rather than evidence that FAPs actively protect muscle mass under normal conditions, though they acknowledge that other FAP-derived factors likely matter for long-term homeostasis, particularly given that transplanting FAPs back into muscle partially rescues the atrophy.

The implications reach well beyond this mouse model. Inflammation has long been recognized as a driver of muscle wasting in cancer cachexia, sarcopenia and chronic disease, and therapies that blunt inflammatory signaling are actively pursued. This study adds a crucial nuance: the same immune cells can be simultaneously protective and destructive, depending on whether one removes the cells or modulates their signals. Physical depletion of myeloid populations worsened wasting, while receptor-level and transcriptional modulation of their inflammatory output preserved muscle. For clinicians and drug developers, the lesson is that the target is not the inflammatory cells themselves but the molecular conversations they conduct, particularly the CXCL1/2-CXCR2 axis and the NF-kappa-B pathway it feeds. As the population ages and muscle wasting syndromes impose enormous clinical burdens, understanding how the death of a single supporting cell type can ignite a self-sustaining cycle of inflammation and proteolysis may prove to be one of the most consequential insights in muscle biology.

Subject of Research: Mechanisms of inflammation-mediated skeletal muscle atrophy following fibro-adipogenic progenitor ablation in mice

Article Title: Fibro‐Adipogenic Progenitor Ablation Triggers Muscle Atrophy Through Cell Death‐Induced Inflammation

Article References: Luo, Y. E., Lee, Y. I., Abe‐Teh, Z., Young, R. Y., Wei‐LaPierre, L., & Barton, E. R. (2026). Fibro‐Adipogenic Progenitor Ablation Triggers Muscle Atrophy Through Cell Death‐Induced Inflammation. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70393. https://doi.org/10.1002/jcsm.70393

Image Credits: AI Generated

DOI: 10.1002/jcsm.70393

Keywords: fibro-adipogenic progenitors, skeletal muscle atrophy, inflammation, CXCR2, NF-kappa-B, neuromuscular junction, macrophages, neutrophils, cachexia, sarcopenia, chemokines, vamorolone

The Regnase proteins, encoded by the ZC3H12 gene family, are RNA-binding endoribonucleases, meaning they cut messenger RNA molecules directly rather than merely tagging them for degradation. Each member carries a conserved CCCH zinc-finger domain paired with a PilT N-terminus-like nuclease domain, a structural combination that coordinates the recognition and cleavage of target transcripts. The founding member, Regnase-1, also known as MCPIP1 or ZC3H12A, was first identified in 2009 as an RNase essential for controlling immune responses by regulating mRNA decay. Its targets include some of the most potent inflammatory messengers in the body: transcripts encoding interleukin-6, interleukin-1 beta, interleukin-12 and tumor necrosis factor. By trimming the lifespan of these mRNAs, Regnase-1 acts as a built-in brake on inflammation.

What makes the brake remarkable is that it is deliberately released when the immune system needs to fire. Following stimulation of Toll-like receptors or interleukin-1 receptors, the I-kappa-B kinase complex phosphorylates Regnase-1, triggering its degradation and allowing inflammatory mRNA to accumulate so that effector programs can begin. In helper T cells, the paracaspase MALT1 cleaves Regnase-1 after T-cell receptor engagement, a mechanism that permits rapid T-cell activation. In group 2 innate lymphoid cells, degradation of Regnase-1 is crucial for responses to interleukin-33 and interleukin-25. These are not accidents of biology; they are controlled, transient losses of enzymatic activity that give immune cells a window in which to respond. The trouble starts, the review argues, when that window fails to close and activity is not restored, prolonging inflammation beyond its useful purpose.

The review is emphatic that the four family members cannot be treated as interchangeable. Regnase-2 appears to serve a homeostatic function that restrains neuroinflammation, while Regnase-3, expressed in myeloid cells, is required for immune homeostasis and regulation of the type I interferon pathway. Recent work also points to crosstalk between Regnase-1 and Regnase-3 in shaping mast cell survival and cytokine expression. Each member differs in cellular distribution, in its repertoire of RNA substrates, and in its contribution across disease stages. Regnase-1 and Regnase-3, for instance, jointly control the expression of Nfkbiz and thereby influence the balance between lymphoid and myeloid lineage commitment. This heterogeneity means that a drug targeting one member may produce entirely different effects depending on which cells express it and when.

Nowhere is that heterogeneity clearer than in the T-cell compartment. Transgenic expression of a catalytically active mutant Regnase-1 in T cells disturbs T-cell development and function, and genetically modulating the protein reveals a critical role in regulatory T cell homeostasis in vivo. In other words, persistently high Regnase-1 activity in selected T-cell populations can itself destabilize immune balance, just as persistently low activity can fuel autoimmunity. A Regnase-1 D141N mutation has been shown to induce CD4-positive T cell-mediated lung granuloma formation through upregulation of the kinase Pim2. Regnase-1 also suppresses the formation of TCF-1-positive precursor exhausted T cells, thereby limiting CAR-T cell responses against acute lymphoblastic leukemia, a finding that has pushed the protein into the spotlight of cancer immunotherapy as well as autoimmunity research.

Beyond T cells, the review catalogs Regnase-1’s influence across an extraordinary range of tissues and disease models. In rheumatoid arthritis, the enzyme post-transcriptionally regulates interleukin-6 production in fibroblast-like synoviocytes, and the RNA-binding protein Roquin-1 cooperates with Regnase-1 to suppress fibroblast growth factor 2 and NF-kappa-B signaling, restraining disease progression. Disrupting the Roquin-1 and Regnase-1 interaction, conversely, induces autoimmunity while enhancing antitumor responses, underscoring the double-edged nature of the pathway. In the skin, keratinocyte-specific loss of Regnase-1 impairs skin integrity and abruptly activates the interleukin-23 and T helper 17 axis, while the enzyme restricts interleukin-17A- and interleukin-17C-dependent skin inflammation and maintains immune homeostasis through regulation of chemokine expression. In ankylosing spondylitis, Regnase-1 regulates inflammation in T cells through the TRAF6 adaptor protein.

The enzyme’s reach extends deep into barrier tissues and even into non-immunological pathology. In the lung, Regnase-1 orchestrates interplay between epithelium and the adaptive immune system to protect against pneumonia, and its deficiency restrains Klebsiella pneumoniae infection by dysregulating type I interferon responses. Pulmonary Regnase-1 in alveolar macrophages degrades transcripts encoding interleukin-6 and platelet-derived growth factor, preventing pulmonary arterial hypertension, while profibrotic functions of group 2 innate lymphoid cells are held in check by the same enzyme. In the kidney, macrophage-specific Regnase-1 attenuates ischemia-reperfusion injury by shaping local inflammatory responses and tissue regeneration, and an interleukin-17-driven inflammatory circuit in renal tubular epithelial cells that amplifies antibody-induced glomerulonephritis is constrained by the protein. In the gut, epithelial Regnase-1 inhibits colorectal tumor growth by degrading NFKBIZ mRNA and thereby damping interleukin-17 signaling, and the enzyme supports colon epithelial regeneration through regulation of mTOR and purine metabolism. Even osteoarthritis and Marfan syndrome have been linked to its activity, with upregulated Regnase-1 suppressing catabolic signaling in chondrocytes and Regnase-1 overexpression proposed as a therapeutic approach for Marfan pathology.

Translational efforts are already under way, and the review highlights one of the most inventive strategies to date: antisense oligonucleotides that bind a stem-loop structure in the 3-prime untranslated region of the Regnase-1 mRNA itself. Regnase-1 normally represses its own translation through this autoregulatory element, so blocking the interaction with a stem-loop-targeting oligonucleotide releases the brake on Regnase-1 protein production. In preclinical models, enhancing Regnase-1 expression this way alleviated inflammatory disease, providing proof of concept that the protein’s output can be therapeutically raised without altering the gene itself. Local protein or gene augmentation strategies, including adeno-associated virus serotype 9 delivery, have likewise shown preclinical promise, while other platforms such as lipid nanoparticles and proteolysis-targeting chimeras remain exploratory. The appeal of these approaches is selectivity: rather than globally suppressing cytokines, they restore a natural quality-control mechanism.

The authors are careful, however, to temper enthusiasm with a sober assessment of what remains unknown. Because Regnase-1 activity is beneficial in some cells and harmful in others, and because both transient loss and persistent excess can disturb homeostasis, any successful therapy must be cell selective, reversible, and confined to an appropriate disease window. Achieving that will demand temporally resolved human samples and direct measurements of protein state, RNA binding, and target decay, rather than relying on static snapshots of messenger RNA abundance. Single-cell and spatial transcriptomic studies of lupus nephritis, rheumatoid arthritis synovium and psoriatic skin have begun to map the cellular landscapes in which these enzymes operate, and techniques such as enhanced cross-linking and immunoprecipitation, RNA velocity analysis and simultaneous epitope and transcriptome measurement offer the resolution needed to track Regnase dynamics in real time.

The broader significance of the review lies in its reframing of post-transcriptional regulation as a central pillar of autoimmunity. For years, immunology has focused on transcription factors and signaling cascades, treating mRNA decay as background housekeeping. The Regnase family demonstrates that the lifespan of an inflammatory transcript can be as decisive as the signal that produced it, and that the same enzyme can protect against pneumonia, prevent pulmonary hypertension, restrain skin inflammation and yet, when mis-timed, contribute to granulomatous lung disease or impaired antitumor immunity. As population studies document rising incidence and co-occurrence of autoimmune disorders across tens of millions of individuals, the search for therapies that correct molecular timing rather than blanket suppression has acquired new urgency. Regnase-1, sitting at the junction of RNA chemistry and immune regulation, may prove to be one of the most instructive targets in that search.

Subject of Research: Post-transcriptional regulation of inflammation by the Regnase family of endoribonucleases in autoimmune diseases

Article Title: The regnase family in autoimmune diseases: a regnase-1-centered perspective on cellular heterogeneity

Article References: Li, Y., Liu, Y., Su, Y., Wang, Y., & Wang, X. (2026). The regnase family in autoimmune diseases: a regnase-1-centered perspective on cellular heterogeneity. Molecular Biology Reports, 53(1), Article 1671. https://doi.org/10.1007/s11033-026-12852-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12852-1

Keywords: Regnase-1, autoimmune diseases, mRNA degradation, endoribonucleases, post-transcriptional regulation, immune homeostasis, T cells, interleukin-6, NF-kappa-B, antisense oligonucleotides, Roquin-1, cellular heterogeneity

Atherosclerosis, the slow accumulation of lipid-rich plaques inside artery walls, remains the leading driver of heart attacks and strokes worldwide. Although statins, anti-inflammatory drugs and surgical procedures have transformed treatment, the global burden of cardiovascular disease keeps climbing, and long-term drug use carries risks of liver and kidney toxicity while surgery remains costly and invasive. That gap has pushed scientists toward unconventional therapeutic targets, and few have attracted more attention than the trillions of microbes inhabiting the intestine. Over the past decade, gut dysbiosis has been linked to metabolic disorders, systemic inflammation and plaque formation, prompting researchers to ask whether traditional formulas, with their holistic orientation, might act partly through these microbial communities.

The research team, led by investigators affiliated with hospitals and universities in Hebei and Yunnan, China, tested FRTM in ApoE-deficient mice, a standard model that develops atherosclerosis when fed a high-fat diet. After eight weeks on the fatty diet, fifty mice were randomly assigned to receive saline, the cholesterol-lowering drug atorvastatin, or FRTM at three doses corresponding to the clinical human dose scaled for rodents. Treatment continued for another eight weeks. Quality control was performed with ultra-performance liquid chromatography coupled to mass spectrometry, which confirmed the presence of signature compounds such as astragaloside A, ferulic acid, puerarin and glycyrrhizic acid, ensuring the preparation matched the marketed product.

The results were unambiguous at the tissue and blood level. Histological staining of the aorta showed that untreated diseased mice had extensive endothelial damage, fibrous plaques, calcification and inflammatory infiltration, while FRTM-treated animals displayed more intact vessel structure, smoother muscle morphology and markedly smaller lesions. Oil Red O staining, which lights up lipid deposits in red, revealed a dose-dependent reduction in plaque area, with the highest dose performing comparably to atorvastatin. Serum analysis told the same story: total cholesterol, triglycerides and LDL cholesterol fell, HDL cholesterol rose, antioxidant enzymes superoxide dismutase and glutathione peroxide recovered their activity, the lipid-damage marker malondialdehyde declined, and the pro-inflammatory cytokines IL-6, IL-1 beta and TNF-alpha dropped significantly.

To probe the mechanism, the team sequenced the 16S rRNA genes of gut bacteria from the cecal contents. Atherosclerosis had visibly disrupted the microbial ecosystem, and FRTM restored it. Diseased mice showed an elevated ratio of Firmicutes to Bacteroidetes, a microbial signature often associated with metabolic disease, and this ratio fell back toward normal after treatment. At the genus level, the capsule boosted beneficial taxa including Lactobacillus, Bifidobacterium, Muribaculaceae, Faecalibaculum and Alloprevotella, while suppressing Turicibacter, a bacterium linked to dietary fat handling and weight change. Each of these organisms carries metabolic credentials: Lactobacillus strains have been shown to ease oxidative stress and modulate cholesterol metabolism, Bifidobacterium reduces visceral fat, Faecalibaculum correlates with production of anti-inflammatory short-chain fatty acids, and Alloprevotella is negatively associated with blood lipids and supports gut barrier integrity through its fermentation products acetate and succinate.

The microbial story then converged on chemistry. Untargeted metabolomics of mouse serum, using principal component and partial least squares discriminant analysis to separate groups, revealed that FRTM shifted dozens of metabolites across multiple pathways, including pyrimidine metabolism and steroid hormone biosynthesis. But one pathway stood out: arachidonic acid metabolism appeared in both the microbiota functional predictions and the metabolomic enrichment analysis, making it the shared link between the gut ecosystem and the host’s inflammatory state. Spearman correlation analysis confirmed significant associations between the FRTM-sensitive bacterial genera and the altered metabolites, suggesting the microbes and the lipid mediators were part of a single connected system.

Arachidonic acid, an omega-6 fatty acid released from membrane phospholipids, is converted by enzymes into prostaglandins, thromboxanes and leukotrienes, lipid messengers that regulate vascular tone, platelet behavior and immune responses. In the FRTM-treated mice, levels of prostaglandin E2, prostaglandin J2 and prostaglandin B2 rose, while the pro-inflammatory prostaglandin G2 and thromboxane B2 fell. That shift matters because PGE2 and PGJ2 are known to steer macrophages, the immune cells that populate plaques, away from a pro-inflammatory M1 state and toward a healing M2 state. PGJ2 activates the nuclear receptor PPAR gamma, which damps NF-kappa-B signaling and cuts production of TNF-alpha and IL-6, while PGE2 engages the EP4 receptor to promote STAT3 phosphorylation and boost the anti-inflammatory cytokine IL-10.

Western blotting and quantitative PCR in the aortas confirmed that these signaling axes had indeed moved. FRTM-treated mice showed increased PPAR gamma phosphorylation, reduced phosphorylation of the NF-kappa-B subunit P65, elevated EP4 expression and a higher ratio of phosphorylated to total STAT3. Gene expression of Il1b, Il6 and Tnfa fell while Il10 rose, and macrophage markers shifted in parallel: the M1 marker Nos2 and its protein product iNOS declined, while the M2 markers CD206 and ARG1 climbed. In short, the capsule appeared to retune both the inflammatory thermostat and the immune cell composition of the diseased artery.

The most provocative experiment came last. The researchers transplanted fecal material from FRTM-treated donor mice into recipient atherosclerotic mice twice weekly for eight weeks, without giving the recipients any drug. The transplanted microbiota partially reproduced the benefits of the capsule itself: recipients developed smaller plaques, better lipid profiles, stronger antioxidant defenses, lower inflammatory cytokines, the same favorable shifts in PPAR gamma, NF-kappa-B and STAT3 signaling, and the same tilt of macrophages toward the M2 phenotype. This suggests that the gut microbes remodeled by FRTM carry a meaningful share of the therapeutic effect, a finding consistent with earlier work showing that pro-inflammatory microbiota can accelerate atherogenesis when transferred between animals.

The authors are careful to flag the limits of their evidence. Because the transplant recipients were not pretreated with antibiotics or raised germ-free, donor microbes may have engrafted only partially, making the fecal transplant results supportive rather than definitive proof of causation. The team also did not perform pharmacological inhibition or genetic knockdown to confirm that PPAR gamma and STAT3 pathways are required for the capsule’s protection, and the aortic sections were taken at plaque-bearing levels rather than the standard aortic valve sinus plane used for precise plaque quantification. Nor did they dissect whether FRTM’s herbal constituents, such as ferulic acid and puerarin, act directly on arachidonic acid-metabolizing enzymes or indirectly through microbial metabolites like short-chain fatty acids and secondary bile acids. Still, the convergence of histology, sequencing, metabolomics, signaling analysis and transplantation paints a coherent picture: a multi-ingredient traditional formula that lowers cholesterol like a statin while simultaneously reprogramming the gut-lipid-immune axis. If future studies in germ-free models and, eventually, human trials bear this out, the humble capsule could join a growing list of therapies that treat the artery by way of the gut.

Subject of Research: Effects of Furong Tongmai capsule on atherosclerosis via gut microbiota, arachidonic acid metabolism and macrophage polarization in ApoE-deficient mice

Article Title: Furong Tongmai Capsule Ameliorates Atherosclerosis in ApoE−/− Mice by Modulating Gut Microbiota, Arachidonic Acid Metabolism and Macrophage Polarization

Article References: Lv, S., Li, H., Wang, Y., Sang, X., Wang, F., Yang, J., Fan, L., Ma, Z., Wang, L., Bian, Y., & Cui, H. (2026). Furong Tongmai Capsule Ameliorates Atherosclerosis in ApoE −/− Mice by Modulating Gut Microbiota, Arachidonic Acid Metabolism and Macrophage Polarization. Journal of Cellular and Molecular Medicine, 30(17), Article e71354. https://doi.org/10.1111/jcmm.71354

Image Credits: AI Generated

DOI: 10.1111/jcmm.71354

Keywords: atherosclerosis, gut microbiota, traditional Chinese medicine, arachidonic acid, macrophage polarization, PPAR gamma, NF-kappa-B, STAT3, fecal microbiota transplantation, metabolomics, ApoE-deficient mice, cardiovascular disease

The core idea is deceptively simple. Natural T cells do not rely on their antigen receptor alone; they depend on co-stimulatory receptors such as CD28 and ICOS, the inducible T cell co-stimulator, to fine-tune activation, survival and differentiation. The researchers reasoned that if a therapeutic T cell receptor could be fused directly to a co-stimulatory signaling domain, every encounter with a tumor cell would deliver not just a recognition signal but a survival and persistence signal at the same time. The construct they engineered, which they call TCR:ICOS, combines the extracellular variable and constant domains of a conventional T cell receptor with a CD28 transmembrane segment and intracellular domains drawn from both ICOS and CD3 epsilon. The result is a single hybrid receptor that couples antigen specificity to co-stimulation in one molecular unit.

The functional consequences in mice were dramatic. T cells carrying the TCR:ICOS receptor showed enhanced, antigen-specific production of inflammatory cytokines, the chemical weapons that help recruit and coordinate an immune attack. More importantly, the cells persisted far longer within tumors than their conventional counterparts, and this persistence translated into clinical outcomes: delayed recurrence of melanoma and, in a subset of animals, complete and durable cures. For a field in which the transience of engineered T cells is a central bottleneck, the demonstration that a receptor-level modification can extend the working lifespan of the cells inside a hostile tumor microenvironment is a significant proof of concept.

Beneath the phenotypic changes lies a defined signaling logic. The team found that TCR:ICOS activation engaged two major pathways, PI3K and NF-kappa B, while paradoxically restraining the activation of AKT, a kinase downstream of PI3K that is often associated with terminal differentiation and metabolic burnout in T cells. This combination appears to be the key to the durability. Sustained PI3K and NF-kappa B signaling supports inflammatory function and survival, while blunted AKT activity helps the cells avoid the hyperactive, exhausted state that typically shortens the life of tumor-infiltrating lymphocytes. When the researchers genetically ablated the ICOS-PI3K pathway, the long-term anti-tumor effects disappeared, confirming that this signaling axis is not a side effect but the mechanistic engine of the durable response.

Single-cell level analysis reinforced the picture of a fundamentally altered differentiation program. TCR:ICOS T cells were enriched for a stem-like state, a less differentiated, self-renewing condition that immunologists regard as the hallmark of long-lived, re-challenge-capable T cell populations. They also showed resistance to exhaustion, the progressive loss of function marked by inhibitory receptors such as PD1, LAG3 and TIM3 that plagues conventional tumor-infiltrating cells. In practical terms, the engineered cells behaved less like short-lived commandos and more like a renewable garrison, capable of maintaining pressure on the tumor over time rather than expending themselves in a single burst of activity.

Translating the concept from mouse to human T cells required an additional round of molecular engineering. Early versions of the hybrid receptor did not express efficiently on the surface of human cells, a common obstacle in receptor design where folding, assembly and trafficking can fail silently. The team solved this by identifying a single amino acid change in the cytosolic tail of the receptor that enabled functional surface expression. Crucially, the optimized receptor avoided two well-known hazards of introducing engineered T cell receptors into patient cells: mispairing with endogenous TCR chains, which can create unpredictable and potentially dangerous specificities, and competition for limited CD3 molecules, which can impair the function of the T cell’s native receptor complex.

The human-cell experiments went beyond a single antigen. The researchers showed that the optimized TCR:ICOS format sustained the functional performance of human T cells across repeated stimulation cycles and could be extended to multiple tumor antigens, including targets relevant to solid cancers such as NY-ESO-1 and ROPN1, without eroding T cell fitness. This uniform applicability matters for the field. Many receptor-engineering advances are idiosyncratic, working for one TCR or one antigen but failing when generalized. A format that preserves T cell quality across different specificities offers a modular platform: any tumor-reactive TCR could, in principle, be equipped with the same built-in co-stimulation and inherit the same durability advantages.

The findings arrive at a moment when the cell therapy field is intensely focused on next-generation designs. Chimeric antigen receptors, or CARs, already incorporate co-stimulatory domains such as CD28 or 4-1BB, and that choice profoundly shapes how CAR T cells persist and differentiate. TCR-based therapies, which can recognize intracellular tumor antigens presented by HLA molecules and therefore access a much larger pool of cancer targets, have lacked an equivalent, systematic way to embed co-stimulation. The TCR:ICOS design fills that gap, and its mechanism, favoring stem-like persistence through PI3K and NF-kappa B while restraining AKT, offers a template that other groups can rationally modify.

There are, of course, steps between a mouse melanoma model and approved therapy. The study was conducted in preclinical systems, and human trials will need to establish safety, particularly given that engineered co-stimulation could, in principle, amplify off-tumor reactivity if a TCR recognizes healthy tissue. Dosing, manufacturing consistency and the behavior of TCR:ICOS cells in the complex, immunosuppressive environment of human solid tumors all remain to be tested. The authors note that the work was supported by the Dutch Cancer Society and a Health Holland public-private partnership, and several team members report pending patents related to the receptor design, signaling commercial interest in bringing the platform toward clinical evaluation.

Even so, the study offers a compelling answer to one of adoptive cell therapy’s most persistent questions: how to make engineered T cells last. By fusing recognition and co-stimulation into a single receptor, the Rotterdam team has shown that durability can be designed into the therapeutic product itself rather than bolted on with cytokines, checkpoint blockade or lymphodepleting chemotherapy. If the format performs in human trials as it has in mice, TCR:ICOS could become a foundational component of fitter, longer-lived T cell products for solid tumors, turning a transient spark of immune attack into a sustained campaign against cancer.

Subject of Research: Engineering T cell receptors with built-in ICOS co-stimulation to extend the durability of adoptive T cell therapy against solid tumors

Article Title: T cell receptors equipped with ICOS provide T cells with durable anti-tumor response

Article References: Marraffa, A., Berrevoets, C., Mosiello, M., Coelho, R. M., Roelofs, D., van Brakel, M., Wijers, R., Kroese, K., Peeters, M. J., Dik, W. A., Kunert, A., Abbott, R. J., Hammerl, D., Schliehe, C., & Debets, R. (2026). T cell receptors equipped with ICOS provide T cells with durable anti-tumor response. Molecular Cancer, 25(1), Article 216. https://doi.org/10.1186/s12943-026-02765-9

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02765-9

Keywords: adoptive T cell therapy, T cell receptor, ICOS, co-stimulation, T cell exhaustion, solid tumors, melanoma, PI3K signaling, NF-kappa B, stem-like T cells, gene engineering, Molecular Cancer

Glioma is the most common malignant primary brain tumor in adults, and its most aggressive form, glioblastoma, carries a median survival measured in months rather than years. The therapeutic arsenal remains painfully thin: surgical resection, radiation, and the chemotherapy drug temozolomide extend life only modestly, and the blood-brain barrier blocks many otherwise promising compounds from ever reaching the tumor. Against this backdrop, scientists have increasingly turned to cell death programs as therapeutic levers. Apoptosis, the quiet and orderly form of cell suicide, has long been the target of conventional cancer drugs, but tumors routinely evolve resistance to it. Pyroptosis, by contrast, is loud, inflammatory, and lytic: cells swell, rupture, and release their contents, simultaneously destroying the tumor cell and sounding an immune alarm.

The molecular machinery of pyroptosis centers on the gasdermin family of proteins. When enzymes such as caspases cleave a gasdermin protein, the released fragment migrates to the cell membrane and punches oligomeric pores into it. The cell loses its ionic balance, swells with water, and ultimately bursts, spilling damage-associated molecular patterns and inflammatory cytokines such as interleukin-1 beta into the tumor microenvironment. One family member in particular, gasdermin E, or GSDME, has attracted intense interest because it can be cleaved by caspase-3, the very executioner enzyme of apoptosis. In principle, this creates a molecular switch: a stimulus that begins as apoptotic can be diverted into pyroptosis when GSDME is present, converting a silent death into an immunostimulatory event capable of reshaping the tumor’s immune landscape.

Recognizing this potential, Hanwen Lu and Zhanxiang Wang of the First Affiliated Hospital of Xiamen University and their collaborators set out to do something that had not been done systematically before: build a dedicated library of pyroptosis-inducing compounds and filter it through the unforgiving realities of brain tumor pharmacology. The team assembled their library by combining commercially available pyroptosis inducers with candidates harvested from an exhaustive mining of the PubMed and Web of Science literature. But identifying a molecule that triggers pyroptosis in a dish is only the first hurdle. For a brain cancer drug, the compound must also survive the gauntlet of drug-likeness filters and, crucially, cross the blood-brain barrier, the tightly sealed endothelial lining that excludes the vast majority of small molecules from the central nervous system.

To solve this, the researchers applied a sequential computational and pharmacological funnel. First came Lipinski’s rule of five, the classic checklist of molecular weight, hydrogen-bond donors and acceptors, and lipophilicity that predicts oral absorbability. Next, they used predictive models of blood-brain barrier permeability, followed by central nervous system multiparameter optimization scoring, a more sophisticated metric that balances multiple physicochemical properties to estimate the likelihood that a molecule will achieve adequate brain exposure without unacceptable side effects. Stringent descriptor-based criteria narrowed the field further, and a final round of pharmacological curation and literature vetting elevated a short list of priority candidates. Rising to the top of that list was diacerein, a drug oncologists had never seriously considered but rheumatologists have prescribed for years.

Diacerein is an anthraquinone derivative that works as a slow-acting anti-osteoarthritic agent, traditionally understood to inhibit interleukin-1 beta signaling in cartilage. Its established safety profile, oral availability, and favorable predicted brain penetration made it an attractive repurposing candidate. In laboratory experiments, the team found that diacerein significantly inhibited the proliferation of glioma cells and suppressed tumor growth in animal models. But the mechanism they uncovered was far more interesting than simple growth arrest. Treatment with diacerein activated caspase-3, the canonical apoptotic executioner, and simultaneously triggered the cleavage of GSDME, the gasdermin protein that converts caspase-3 activity into pyroptotic membrane rupture. In other words, the drug appeared to push glioma cells down a hybrid death pathway that begins with apoptosis and culminates in pyroptosis-like lysis.

To confirm that GSDME was not merely a bystander in this process, the researchers performed loss-of-function experiments. When they knocked down GSDME in glioma cells, the cytotoxic punch of diacerein was substantially blunted: cell viability recovered, and the drug’s killing efficiency dropped. This partial rescue demonstrates that GSDME is functionally required for a significant share of diacerein-induced glioma cell death, anchoring the drug’s effect in the pyroptotic pathway the screen was designed to find. The team also traced changes in inflammation-related signaling, observing reduced activity along the interleukin-1 beta, NF-kappa B, and phosphorylated STAT3 axes. Because these pathways sit at the heart of macrophage-mediated inflammation, the authors suggest the drug may also alter macrophage-related immune dynamics within the tumor microenvironment in living animals, a possibility with major implications given the prominent role of tumor-associated macrophages in glioma immunosuppression.

The implications extend beyond a single molecule. The study validates a repurposing strategy that begins with a cell death mechanism rather than a molecular target, then filters candidate drugs through the pharmacological constraints of the diseased tissue. This pyroptosis-oriented pipeline could in principle be rerun for other cancers of the central nervous system, or adapted to other lytic death programs such as necroptosis and ferroptosis. It also illustrates the growing power of literature mining as a discovery tool: by systematically extracting pyroptosis-inducing activity from thousands of published pharmacological studies, the team assembled a candidate pool that no single laboratory’s compound collection would have contained. The approach effectively converts the accumulated knowledge of pharmacology into a searchable, filterable database of mechanism-directed therapeutics.

Considerable work remains before diacerein could reach glioma patients. The doses used in laboratory and animal studies may not map directly onto the exposures achievable and tolerable in humans, and the authors evaluated brain exposure using liquid chromatography-tandem mass spectrometry methods developed specifically for this study, but clinical pharmacokinetics in glioma patients, where the blood-brain barrier is often locally disrupted yet heterogeneously intact, will need dedicated investigation. The precise molecular target through which diacerein initiates caspase-3 activation in glioma cells also remains to be fully defined, and the immunological consequences of triggering pyroptosis inside the brain, an organ exquisitely sensitive to inflammation, must be carefully characterized. Nevertheless, the fact that diacerein is already an approved, well-characterized medicine with a known safety record could substantially shorten the path from bench to bedside, potentially through investigator-initiated clinical trials in recurrent glioma, where new options are desperately needed and the regulatory bar for repurposed drugs is lower than for entirely novel agents.

For a disease that has defeated nearly every therapeutic innovation thrown at it, the idea that an arthritis pill sitting in pharmacy shelves worldwide might recruit the immune system against glioma through gasdermin pores is the kind of unexpected twist that drug repurposing was made for. The Xiamen team’s work provides both a concrete candidate and a reusable discovery framework, suggesting that the next breakthrough in brain cancer may not come from a molecule designed from scratch, but from an old drug viewed through an entirely new biological lens.

Subject of Research: Pyroptosis-oriented drug repurposing identifies diacerein as a therapeutic candidate for glioma

Article Title: Pyroptosis-oriented drug discovery identifies diacerein as a promising therapeutic candidate for glioma

Article References: Lu, H., & Wang, Z. (2026). Pyroptosis-oriented drug discovery identifies diacerein as a promising therapeutic candidate for glioma. BMC Medicine. https://doi.org/10.1186/s12916-026-05187-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05187-y

Keywords: glioma, diacerein, pyroptosis, GSDME, caspase-3, drug repurposing, blood-brain barrier, immune microenvironment, macrophage, NF-kappa B, IL-1 beta, BMC Medicine